MBL Venture Capital, also known as mblVC, is a venture capital firm founded in 2000. The firm is a subsidiary of Medical & Biological Laboratories Co., Ltd., a Japanese company that specializes in the research and manufacture of in-vitro diagnostics (IVDs) and research reagents. mblVC is primarily based in Tokyo, Japan although it also has an additional office in Nagoya, Japan. The firm’s most recent investment is in Sentien Biotechnologies during September 2018, a company developing blood conditioning therapies for patients with critical illnesses.
mblVC primarily funds companies that are based in Japan and the United States, although it also invests in companies from Europe. The firm specializes on investing in companies that are operating in these industries: biotechnology, life science, pharmaceuticals, and healthcare information technology. It finances companies in various stages of development, from seed-stage to pre-IPO. The firm provides $1-2 million for initial investment and $2-3 million for each portfolio company in total.